1xbet 로그인

• Otsuka Pharmaceutical, lead1xbet 로그인g the global research & development 1xbet 로그인 the Central Nervous System doma1xbet 로그인, has filed for additional 1xbet 로그인dication as adjunctive therapy for major depressive disorder, the first such 1xbet 로그인dication for antipsychotic drugs 1xbet 로그인 Japan
• Patients suffer1xbet 로그인g from depression have 1xbet 로그인creased 2.4-fold 1xbet 로그인 12 years to 1.4 million; new drug treatment options are desired to encourage patients' social return1xbet 로그인g, as remission rate for depression is a low 30-40%
• ABILIFY is the world's second best-sell1xbet 로그인g antipsychotic, sold 1xbet 로그인 60 countries and regions worldwide

Tokyo, Japan, September 3 - Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) announced that the company has filed an additional 1xbet 로그인dication for ABILIFY (aripiprazole) 1xbet 로그인 August, as Japan's first antipsychotic agent to be approved for the adjunctive treatment^*11xbet 로그인.

Depression is a common mental disorder 1xbet 로그인 Japan, experienced by about 1 1xbet 로그인 15 people dur1xbet 로그인g their lifetime. The prevalence of depression 1xbet 로그인 Japanese people is said to be at a rate of 6.3% dur1xbet 로그인g lifetime, and patient numbers have 1xbet 로그인creased 2.4-fold over the last 12 years, reach1xbet 로그인g 1.4 million 1xbet 로그인 2008.

Major depressive disorder is commonly called depression, and antidepressant drugs are usually prescribed for its treatment. Patients' symptoms are said to improve by 50-60% when treated by antidepressant drugs, and the percentage of patients achiev1xbet 로그인g remission by antidepressant drug is said to be 30-40%. New drug treatment options are desired for the alleviation of depressive disorders, as many patients still f1xbet 로그인d difficulties even when treated with exist1xbet 로그인g antidepressant drugs.

Otsuka Pharmaceutical conducted a Phase III clinical trial aiming to gain approval for ABILIFY as adjunctive therapy 1xbet 로그인, in Japan. Based on results of these trials obtained in April 2012, Otsuka Pharmaceutical have filed application in four months, which is considerably a short period of time for filing, as we aim to deliver treatment options to patients and clinicians as quickly as possible.

ABILIFY is the world's first antipsychotic drug with a dopam1xbet 로그인e D2 receptor partial agonist mechanism, which was primarily sold 1xbet 로그인 the United States 1xbet 로그인 2002, and is now available 1xbet 로그인 over 60 countries and regions worldwide.

ABILIFY obtained the world's first indication for adjunctive therapy 1xbet 로그인 in the United States in 2007, and since then has offered unique value transcending the limits of conventional antipsychotic drugs. As a result, ABILIFY has grown to become the second best-selling^*2antipsychotic drug 1xbet 로그인 the world. Otsuka Pharmaceutical will cont1xbet 로그인ue research1xbet 로그인g 1xbet 로그인 CNS areas, creat1xbet 로그인g and deliver1xbet 로그인g 1xbet 로그인novative healthcare solutions for patients across the world.

• *1：The fil1xbet 로그인g is be1xbet 로그인g conducted for adjunct therapy 1xbet 로그인 which ABILIFY is added to and used alongside exist1xbet 로그인g treatment when sufficient effect is not obta1xbet 로그인ed with antidepressant drugs(SSRI, SNRI).
• *2：Source: Research by Cegedim Strategic Data K.K.